Olaparib has also been shown to be effective in preclinical models of MCL harbouring ATM mutation [9], which is present in 41–56% of MCL and 13–20% of DLBCL patients [10–12], and also impairs the DSB repair pathway. Here, ATM is linked to mantle cell lymphoma.